MDRNA Releases In Vivo Cancer Data, Could Advance Bladder Cancer Program to Clinic First

While MDRNA's liver cancer program has been its lead drug-development effort since early 2009, the firm's work in bladder cancer has been so promising that it may jump to the head of the pipeline, according to a top official.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.